Financhill
Buy
60

EDAP Quote, Financials, Valuation and Earnings

Last price:
$3.69
Seasonality move :
28.73%
Day range:
$3.61 - $3.80
52-week range:
$1.21 - $4.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.96x
P/B ratio:
5.02x
Volume:
46.9K
Avg. volume:
63.1K
1-year change:
67.27%
Market cap:
$137.6M
Revenue:
$69.4M
EPS (TTM):
-$0.58

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EDAP
EDAP TMS SA
$20.5M -$0.13 -5.42% -134.66% $5.83
AKTX
Akari Therapeutics Plc
-- -$0.06 -- -53.67% $3.53
ASND
Ascendis Pharma A/S
$286.8M -$0.16 205.89% -76.94% $259.87
CLLS
Cellectis SA
$11.9M -$0.11 -5.7% -56.58% $7.20
DBVT
DBV Technologies SA
$1.2M -$0.23 -- -80.11% $39.69
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EDAP
EDAP TMS SA
$3.68 $5.83 $137.6M -- $0.00 0% 1.96x
AKTX
Akari Therapeutics Plc
$0.28 $3.53 $10.1M -- $0.00 0% --
ASND
Ascendis Pharma A/S
$202.99 $259.87 $12.4B -- $0.00 0% 16.98x
CLLS
Cellectis SA
$4.41 $7.20 $442.4M -- $0.00 0% 5.49x
DBVT
DBV Technologies SA
$17.01 $39.69 $465.4M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EDAP
EDAP TMS SA
24.46% 0.007 10.36% 0.94x
AKTX
Akari Therapeutics Plc
8.54% -2.274 6.43% 0.16x
ASND
Ascendis Pharma A/S
127.22% -0.633 7.87% 0.68x
CLLS
Cellectis SA
54.27% 0.076 41.7% 1.35x
DBVT
DBV Technologies SA
23.24% -3.671 5.85% 1.41x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EDAP
EDAP TMS SA
$7M -$5.8M -45.27% -56.97% -35.49% -$5.2M
AKTX
Akari Therapeutics Plc
-- -$2.2M -82.27% -91.86% -- -$2.1M
ASND
Ascendis Pharma A/S
$219.4M $12.9M -34.4% -880.05% 5.15% $1.3M
CLLS
Cellectis SA
$30M $5.9M -15.69% -31.08% 16.76% -$4M
DBVT
DBV Technologies SA
-$4.3M -$36.9M -211.46% -280.59% -- -$32.5M

EDAP TMS SA vs. Competitors

  • Which has Higher Returns EDAP or AKTX?

    Akari Therapeutics Plc has a net margin of -36.13% compared to EDAP TMS SA's net margin of --. EDAP TMS SA's return on equity of -56.97% beat Akari Therapeutics Plc's return on equity of -91.86%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    EDAP TMS SA
    43.02% -$0.16 $36.3M
    AKTX
    Akari Therapeutics Plc
    -- -$0.19 $24.8M
  • What do Analysts Say About EDAP or AKTX?

    EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 58.51%. On the other hand Akari Therapeutics Plc has an analysts' consensus of $3.53 which suggests that it could grow by 1154.29%. Given that Akari Therapeutics Plc has higher upside potential than EDAP TMS SA, analysts believe Akari Therapeutics Plc is more attractive than EDAP TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    EDAP TMS SA
    1 2 0
    AKTX
    Akari Therapeutics Plc
    2 0 0
  • Is EDAP or AKTX More Risky?

    EDAP TMS SA has a beta of -0.260, which suggesting that the stock is 126.03% less volatile than S&P 500. In comparison Akari Therapeutics Plc has a beta of 0.272, suggesting its less volatile than the S&P 500 by 72.768%.

  • Which is a Better Dividend Stock EDAP or AKTX?

    EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Akari Therapeutics Plc pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or AKTX?

    EDAP TMS SA quarterly revenues are $16.2M, which are larger than Akari Therapeutics Plc quarterly revenues of --. EDAP TMS SA's net income of -$5.9M is higher than Akari Therapeutics Plc's net income of -$6.4M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Akari Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.96x versus -- for Akari Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    EDAP TMS SA
    1.96x -- $16.2M -$5.9M
    AKTX
    Akari Therapeutics Plc
    -- -- -- -$6.4M
  • Which has Higher Returns EDAP or ASND?

    Ascendis Pharma A/S has a net margin of -36.13% compared to EDAP TMS SA's net margin of -28.55%. EDAP TMS SA's return on equity of -56.97% beat Ascendis Pharma A/S's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    EDAP TMS SA
    43.02% -$0.16 $36.3M
    ASND
    Ascendis Pharma A/S
    87.87% -$1.17 $751.5M
  • What do Analysts Say About EDAP or ASND?

    EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 58.51%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $259.87 which suggests that it could grow by 28.02%. Given that EDAP TMS SA has higher upside potential than Ascendis Pharma A/S, analysts believe EDAP TMS SA is more attractive than Ascendis Pharma A/S.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    EDAP TMS SA
    1 2 0
    ASND
    Ascendis Pharma A/S
    13 0 0
  • Is EDAP or ASND More Risky?

    EDAP TMS SA has a beta of -0.260, which suggesting that the stock is 126.03% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.4%.

  • Which is a Better Dividend Stock EDAP or ASND?

    EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or ASND?

    EDAP TMS SA quarterly revenues are $16.2M, which are smaller than Ascendis Pharma A/S quarterly revenues of $249.6M. EDAP TMS SA's net income of -$5.9M is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.96x versus 16.98x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    EDAP TMS SA
    1.96x -- $16.2M -$5.9M
    ASND
    Ascendis Pharma A/S
    16.98x -- $249.6M -$71.3M
  • Which has Higher Returns EDAP or CLLS?

    Cellectis SA has a net margin of -36.13% compared to EDAP TMS SA's net margin of 1.68%. EDAP TMS SA's return on equity of -56.97% beat Cellectis SA's return on equity of -31.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    EDAP TMS SA
    43.02% -$0.16 $36.3M
    CLLS
    Cellectis SA
    85.76% $0.01 $219.7M
  • What do Analysts Say About EDAP or CLLS?

    EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 58.51%. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 63.27%. Given that Cellectis SA has higher upside potential than EDAP TMS SA, analysts believe Cellectis SA is more attractive than EDAP TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    EDAP TMS SA
    1 2 0
    CLLS
    Cellectis SA
    2 2 0
  • Is EDAP or CLLS More Risky?

    EDAP TMS SA has a beta of -0.260, which suggesting that the stock is 126.03% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.823, suggesting its more volatile than the S&P 500 by 182.278%.

  • Which is a Better Dividend Stock EDAP or CLLS?

    EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or CLLS?

    EDAP TMS SA quarterly revenues are $16.2M, which are smaller than Cellectis SA quarterly revenues of $35M. EDAP TMS SA's net income of -$5.9M is lower than Cellectis SA's net income of $586.4K. Notably, EDAP TMS SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.96x versus 5.49x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    EDAP TMS SA
    1.96x -- $16.2M -$5.9M
    CLLS
    Cellectis SA
    5.49x -- $35M $586.4K
  • Which has Higher Returns EDAP or DBVT?

    DBV Technologies SA has a net margin of -36.13% compared to EDAP TMS SA's net margin of --. EDAP TMS SA's return on equity of -56.97% beat DBV Technologies SA's return on equity of -280.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    EDAP TMS SA
    43.02% -$0.16 $36.3M
    DBVT
    DBV Technologies SA
    -- -$1.21 $68.9M
  • What do Analysts Say About EDAP or DBVT?

    EDAP TMS SA has a consensus price target of $5.83, signalling upside risk potential of 58.51%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 133.35%. Given that DBV Technologies SA has higher upside potential than EDAP TMS SA, analysts believe DBV Technologies SA is more attractive than EDAP TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    EDAP TMS SA
    1 2 0
    DBVT
    DBV Technologies SA
    4 0 1
  • Is EDAP or DBVT More Risky?

    EDAP TMS SA has a beta of -0.260, which suggesting that the stock is 126.03% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.

  • Which is a Better Dividend Stock EDAP or DBVT?

    EDAP TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EDAP TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or DBVT?

    EDAP TMS SA quarterly revenues are $16.2M, which are larger than DBV Technologies SA quarterly revenues of --. EDAP TMS SA's net income of -$5.9M is higher than DBV Technologies SA's net income of -$33M. Notably, EDAP TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EDAP TMS SA is 1.96x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    EDAP TMS SA
    1.96x -- $16.2M -$5.9M
    DBVT
    DBV Technologies SA
    -- -- -- -$33M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will The Magnificent 7 Stocks Go Up This Year?
Will The Magnificent 7 Stocks Go Up This Year?

2025 was another banner year for the Magnificent Seven stocks,…

Why Did Planet Labs Stock Rally So Much?
Why Did Planet Labs Stock Rally So Much?

Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…

Why Did Stan Druckenmiller Sell Broadcom Stock?
Why Did Stan Druckenmiller Sell Broadcom Stock?

In Q3, legendary macro investor Stan Druckenmiller sold his entire…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
65
Is GOOG Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Buy
51
Is GOOGL Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Alerts

Buy
100
ATGL alert for Jan 10

Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.

Buy
65
RGC alert for Jan 10

Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.

Sell
50
NAIL alert for Jan 10

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock